New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia
Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Giovanni Martinelli(University of Bologna), Enrico Maffini(Istituto di Ematologia di Bologna), Giulia Daghia(University of Ferrara), Claudio Cerchione(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Francesco Saraceni(Ospedale "Santa Maria delle Croci" di Ravenna), Michela Rondoni(Azienda Unità Sanitaria Locale Della Romagna), Evita Massari(Azienda Unità Sanitaria Locale Della Romagna), Attilio Olivieri(Ospedali Riuniti di Ancona)
Cited by 4
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644